Form 4: Rapport Therapeutics Director Receives Stock Options

Director Reid M. Huber was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Reid M. Huber acquired 15,200 stock options in Rapport Therapeutics, Inc. (RAPP).
• The options have an exercise price of $35.21 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $35.21 exercise price.

Future Outlook

The options vest on the earlier of June 10, 2027, or the date of the next Annual Meeting of Stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The vesting schedule of one year or the next annual meeting is consistent with standard corporate governance practices for board compensation in the life sciences industry.

Stakeholder Impact

• Minor dilution impact for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 10, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Form 4, Director Compensation, Stock Options, Insider Transaction